ライフサイエンスコーパス: thrombophilia

1 rrent pregnancy loss in women with inherited thrombophilia.

2 age, in the presence or absence of inherited thrombophilia.

3 e these complications in pregnant women with thrombophilia.

4 sociated with hemolysis, marrow failure, and thrombophilia.

5 antiphospholipid syndrome (APS) or inherited thrombophilia.

6 y associated with clotting hyperactivity and thrombophilia.

7 ng VTE compared with those without inherited thrombophilia.

8 events than women who screened negative for thrombophilia.

9 e on the cost-effectiveness of screening for thrombophilia.

10 uate the cost-effectiveness of screening for thrombophilia.

11 usly healthy patients, in those with genetic thrombophilia.

12 patients were offered testing for heritable thrombophilia.

13 V Leiden (FVL), is the most common cause of thrombophilia.

14 uding those with and those without inherited thrombophilia.

15 r genetic defects in factor V or concomitant thrombophilia.

16 of BCS comprises several diseases leading to thrombophilia.

17 athophysiology of inherited risk factors for thrombophilia.

18 s thrombosis can be attributed to hereditary thrombophilia.

19 mal association between perinatal stroke and thrombophilia.

20 tment modalities are variables implicated in thrombophilia.

21 pecific perinatal stroke diseases with known thrombophilias.

22 es were observed in 12, including all common thrombophilias.

23 s did not differ in patients with or without thrombophilia (1.34 [0.73-2.46]; p=0.351).

24 sk of fetal loss was increased in women with thrombophilia (168/571 vs 93/395; odds ratio 1.35 [95% C

25 Of 843 women with thrombophilia 571 had 1524 pregnancies; of 541 control w

26 e, 13%; and (5) psychosocial issues, 7%, and thrombophilia, 7%.

27 identify potentially high-risk patients for thrombophilia and consider testing for inherited risk fa

28 th screening, in order to detect one case of thrombophilia and indeed to prevent a subsequent venous

29 ng pregnancy outcome in women with inherited thrombophilia and placenta-mediated pregnancy complicati

30 in (LMWH) vs no LMWH in women with inherited thrombophilia and prior late (>/=10 weeks) or recurrent

31 C3 and factor D prevented both the systemic thrombophilia and renal TMA phenotypes.

32 ute risk) of gestational VTE associated with thrombophilia and to see whether these risk factors are

33 increased specific activity associated with thrombophilia and used it to improve gene therapy of hem

34 reeclampsia is also associated with maternal thrombophilias and decidual hemorrhage, which form throm

35 inatal stroke include hereditary or acquired thrombophilias and environmental factors.

36 current thrombosis, a history of thrombosis, thrombophilia, and a history of poor pregnancy outcome,

37 of gestational VTE associated with heritable thrombophilia, and current recommendations for antenatal

38 better RBC quality, biomarkers of hemolysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer

39 moking, chronic disease, malignancy, genetic thrombophilia, and procoagulant markers) were adjusted f

40 ologic evaluation for inherited and acquired thrombophilias, and multidisciplinary approaches to trea

41 The most common causes of hereditary thrombophilia are reviewed with an emphasis on resistanc

42 The hereditary thrombophilias are a group of inherited conditions that

43 Thrombophilias are common disorders that increase the ri

44 t the involvement of thrombotic processes in thrombophilia-associated placental failure.

45 egnancy complications in pregnant women with thrombophilia at high risk of these complications and is

46 , we enrolled consenting pregnant women with thrombophilia at increased risk of venous thromboembolis

47 betes mellitus was striking (hazard ratio of thrombophilia-ATE association was 1.41 in nondiabetics v

48 Future studies on thrombophilia-ATE risk should focus on high-risk populat

49 istory of thrombosis, inherited and acquired thrombophilia, certain medical conditions, and complicat

50 Congenital and acquired thrombophilias contribute to the pathophysiological proc

51 was inducible in 27% of MINOCA patients, and thrombophilia disorders were detected in 14%.

52 first episode of VTE, testing for heritable thrombophilia does not allow prediction of recurrent VTE

53 n (Aalpha R554C-albumin), is associated with thrombophilia ("Dusart Syndrome"), and is characterized

54 rolled in the European Prospective Cohort on Thrombophilia (EPCOT).

55 Women with familial thrombophilia, especially those with combined defects or

56 Standardized thrombophilia evaluations were performed after 12 months

57 erse diseases as hereditary hemochromatosis, thrombophilias, familial cancer predispositions, and pha

58 de evidence that unselected women with these thrombophilias have an increased risk of gestational VTE

59 absence of laboratory evidence of heritable thrombophilia (hazard ratio 1.50 [95% CI 0.82-2.77]; p=0

60 tional components of an extensive laboratory thrombophilia (i.e., hypercoagulability) panel at the ti

61 gest screening for these forms of hereditary thrombophilia in children with VTE and their relatives.

62 Understanding thrombophilia in perinatal stroke informs pathogenesis m

63 ng for the causes of hereditary and acquired thrombophilia in selected subsets of patients.

64 their relatives were screened for inherited thrombophilia including proteins C and S and antithrombi

65 sing anti-C5 monoclonal antibodies prevented thrombophilia induced by aPL.

66 important to know whether factors other than thrombophilia influence their risk for thrombosis.

67 Whether hereditary thrombophilia interacts with traditional cardiovascular

68 tion developed renal TMA as well as systemic thrombophilia involving large blood vessels in multiple

69 Hereditary thrombophilia is associated with a slightly increased ri

70 Although thrombophilia is associated with a substantial increase

71 the current status of laboratory testing for thrombophilia is discussed.

72 regnancy outcomes in women with constitutive thrombophilia is uncertain.

73 Based on existing evidence, screening for thrombophilia is unlikely to be cost-effective.

74 Screening for inherited thrombophilia (IT) is controversial; persons at high ris

75 tudy was to estimate the impact of inherited thrombophilia (IT) on the risk of venous thromboembolism

76 The presence of such genetic thrombophilia markers as factor V Leiden, prothrombin 20

77 hrombotic state, we postulated that maternal thrombophilia might be a risk factor for fetal loss.

78 (odds ratio [OR] 21.7, 95% CI 6.8 to 69.1), thrombophilia (OR 25.6, 95% CI 9.2 to 71.2), diabetes me

79 basis of relative prevalences of the various thrombophilias, patients can be classified as "strongly"

80 known as the Genetic Analysis of Idiopathic Thrombophilia project (GAIT).

81 recent discoveries of two relatively common thrombophilias, resistance to activated protein C associ

82 Furthermore we have reported genetic thrombophilia results for 271 recipients.

83 e of patient groups, selective history-based thrombophilia screening has been shown to be more cost-e

84 However, the potential cost-effectiveness of thrombophilia screening may be improved if the screening

85 and underscores the importance of pediatric thrombophilia screening programs.

86 ymorphism (n = 279), and women with negative thrombophilia screening results (n = 796).

87 prior fetal death), and women with negative thrombophilia screening results as control women (n = 79

88 these data suggest that women with high-risk thrombophilia should be considered for antenatal thrombo

89 nine of 11 participating centres and for all thrombophilia subgroups.

90 atal thromboprophylaxis in women with severe thrombophilia such as homozygous factor V Leiden mutatio

91 n avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transi

92 , as well as the benefits and limitations of thrombophilia testing, will be discussed.

93 ncy terminations had been done in women with thrombophilia than in controls (odds ratio 2.9 [1.8-4.8]

94 ss-linking potential, and contributes to the thrombophilia that characterizes the "Dusart Syndrome."

95 ents), and suggest some guidelines regarding thrombophilia treatment and the management of thrombotic

96 Genetic thrombophilia was associated with clinical recurrence in

97 Thrombophilia was associated with elevated risk of ATE (

98 Thrombophilia was not associated with increased risk of

99 c kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA co

100 c kidney disease, liver disease, cancer, and thrombophilia were more likely to be initiated on VKA co

101 Genetic or acquired conditions causing thrombophilia were rare.

102 Moreover, the association of thrombophilia with ATE tended to be stronger in females

103 Overall, the association of thrombophilia with ATE tended to be stronger in the pres

104 actors, especially the synergistic effect of thrombophilia with diabetes mellitus was striking (hazar

105 s before 15 weeks' gestation) and a negative thrombophilia workup.